Drugs / BPL-003
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05870540 | Sep 2023 → Mar 2025 | — | Beckley Psytech Limited | Completed | No outcome recorded |
| Phase 2 | NCT05674929 | May 2023 → Oct 2024 | alcohol-related disorders | Beckley Psytech Limited | Completed | No outcome recorded |
| Phase 2 | NCT05660642 | Feb 2023 → Nov 2026 expected | — | Beckley Psytech Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPL-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05870540 ↗ |
| Route | Intranasal | “two single doses of BPL-003, given intranasally” NCT05660642 ↗ |